<a href=Pfizer” width=”400″ />

Takeda Pharma and Altos Therapeutics have entered a definitive agreement to jointly develop a treatment for gastroparesis (GP).

According to the agreement, the two partners will develop the compound ATC-1906 and its dopamine receptor antagonist mechanism of action. Takeda Pharma will also have an exclusive option to acquire Altos Therapeutics.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Takeda Pharma will make an upfront payment to Altos Therapeutics and assume control over the development and commercialisation of ATC-1906, while Altos Therapeutics will be eligible for additional payments linked with key commercial milestones of the compound.

Pfizer has announced that it will acquire majority assets of BIND Therapeutics for a consideration of $20m.

Following the transaction, Pfizer will acquire all the assets and certain contractual liabilities of BIND.

The transaction is expected to be completed in the third quarter of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Huons Global has announced that it will raise gross proceeds of $250.3m through public offering of its 4,959,779 common stock shares.

The subscription period for the offering will start from 22 July and complete by 10 August.

“Following the transaction, Pfizer will acquire all the assets and certain contractual liabilities of BIND.”

Nantong Jinghua Pharma plans to raise up to $165.5m of funds through a private placement of its shares.

The company intends to invest the funds for the acquisition of Alpha Pharma.

CStone Pharma has raised $150m in a series A venture financing round. The financing round was led by Oriza Seeds Venture Capital Consultancy and WuXi Healthcare Ventures.

The company plans to use the funds to further advance its clinical-stage programmes and work on new innovations to treat patient in China and all over the world.

Image: Pfizer has announced that it will acquire majority assets of BIND Therapeutics. Photo: courtesy of Neruru via Wikipedia.